Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
NLS Pharmaceutics AG - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
NLSP
Nasdaq
8731
https://nlspharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for NLS Pharmaceutics AG
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
- Apr 19th, 2024 9:00 pm
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
- Mar 22nd, 2024 8:30 pm
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
- Mar 20th, 2024 5:40 pm
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
- Mar 20th, 2024 11:30 am
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
- Mar 14th, 2024 12:00 pm
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
- Mar 11th, 2024 11:00 am
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
- Feb 23rd, 2024 12:30 pm
Notice of Deficiency with Nasdaq Continued Listing Requirements
- Jan 12th, 2024 9:30 pm
NLS Pharmaceutics CEO Issues Letter to Shareholders
- Dec 29th, 2023 9:30 pm
10 Best Debt Free Penny Stocks To Buy Now
- Dec 4th, 2023 12:21 pm
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.
- Dec 1st, 2023 12:30 pm
NLS Pharmaceutics Announces Election of Additional Board Members
- Nov 28th, 2023 12:30 pm
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia
- Nov 27th, 2023 1:30 pm
NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan
- Nov 16th, 2023 1:00 pm
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification
- Oct 25th, 2023 8:30 pm
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions
- Oct 19th, 2023 9:00 pm
NLS Pharmaceutics Announces Company Update on Strategic Partnerships
- Oct 12th, 2023 1:40 pm
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol
- Jul 3rd, 2023 11:00 am
NLS Pharmaceutics Releases the Results from its Annual General Meeting
- Jun 30th, 2023 8:05 pm
NLS Pharmaceutics Company Update and Webcast Today Postponed
- Jun 30th, 2023 12:00 pm
Scroll